# US 2018/0023094 A1 · Recombinant aav variants and uses thereof

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2018/0023094 A1
- Document ID: US20180023094A1
- Status: Published application
- Kind: A1
- Application number: 15/520,977
- Filed: 2015-10-21
- Published: 2018-01-25
- Earliest claimed: 2014-10-21
- Assignees: University of Massachusetts
- Applicants: University of Massachusetts
- Inventors: Guangping Gao; Jun Xie; Terence Flotte
- Web page: https://patentgrep.com/patent/US20180023094A1

## CPC

- C12N 15/86: Viral vectors
- A01K 67/0275: Genetically modified vertebrates, e.g. transgenic
- A61K 48/0066: {Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid}
- C07K 14/005: from viruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- C12N 15/113: Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; {Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing (when used in plants C12N15/8218)}
- C12N 15/8509: {for producing genetically modified animals, e.g. transgenic}
- A01K 2217/05: Animals comprising random inserted nucleic acids (transgenic)
- A01K 2217/206: Animal model comprising tissue-specific expression system, e.g. tissue specific expression of transgene, of Cre recombinase
- A01K 2267/03: Animal model, e.g. for test or diseases
- A61K 35/00: Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- C12N 2310/113: targeting other non-coding nucleic acids, e.g. antagomirs
- C12N 2310/141: MicroRNAs, miRNAs
- C12N 2750/14121: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2750/14122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2750/14141: Use of virus, viral particle or viral elements as a vector
- C12N 2750/14143: viral genome or elements thereof as genetic vector
- C12N 2750/14145: Special targeting system for viral vectors
- C12N 2810/6027: ssDNA viruses
- C12N 2830/008: cell type or tissue specific enhancer/promoter combination
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A01K: ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

The disclosure in some aspects relates to recombinant adeno-associated viruses having distinct tissue targeting capabilities. In some aspects, the disclosure relates to gene transfer methods using the recombinant adeno-associated viruses. In some aspects, the disclosure relates to isolated AAV capsid proteins and isolated nucleic acids encoding the same.

## Claims

### Claim 1

A recombinant expression vector comprising a sequence selected from the group consisting of: SEQ ID NO: 1 to 47, or a fragment thereof that does not encode a peptide that is identical to a sequence of any one of SEQ ID NOs: 98 to 100.

### Claim 2

An isolated AAV capsid protein comprising an amino acid sequence selected from the group consisting of: SEQ ID NOs: 51 to 97.

### Claim 3

An isolated AAV capsid protein comprising a sequence selected from the group consisting of: SEQ ID NOs: 51 to 61, wherein an amino acid of the sequence that is not identical to a corresponding amino acid of the sequence set forth as SEQ ID NO: 98 is replaced with a conservative substitution.

### Claim 4

An isolated AAV capsid protein comprising a sequence selected from the group consisting of: SEQ ID NOs: 62 to 67, wherein an amino acid of the sequence that is not identical to a corresponding amino acid of the sequence set forth as SEQ ID NO: 99 is replaced with a conservative substitution.

### Claim 5

An isolated AAV capsid protein comprising a sequence selected from the group consisting of: SEQ ID NOs: 68 to 97, wherein an amino acid of the sequence that is not identical to a corresponding amino acid of the sequence set forth as SEQ ID NO: 100 is replaced with a conservative substitution.

### Claim 6 (depends on 2, 3, 4, 5)

A peptide fragment of the isolated AAV capsid protein of any one of claims 2 to 5 that is not identical to a sequence of any one of SEQ ID NOs: 98 to 100.

### Claim 7 (depends on 6)

An isolated AAV capsid protein comprising the peptide fragment of claim 6.

### Claim 8 (depends on 2, 3, 4, 5)

An recombinant expression vector comprising a nucleic acid sequence encoding the isolated AAV capsid protein of any one of claims 2 to 5.

### Claim 9 (depends on 2, 3, 4, 5)

A composition comprising the isolated AAV capsid protein of any one of claims 2 to 5.

### Claim 10 (depends on 2, 3, 4, 5)

A composition comprising the isolated AAV capsid protein of any one of claims 2 to 5 and a pharmaceutically acceptable carrier.

### Claim 11 (depends on 2, 3, 4, 5)

A recombinant AAV (rAAV) comprising the isolated AAV capsid protein of any one of claims 2 to 5.

### Claim 12 (depends on 11)

A composition comprising the recombinant rAAV of claim 11.

### Claim 13 (depends on 12)

The composition of claim 12 further comprising a pharmaceutically acceptable carrier.

### Claim 14

A host cell containing a nucleic acid that comprises a coding sequence selected from the group consisting of: SEQ ID NO: 1 to 47 that is operably linked to a promoter.

### Claim 15 (depends on 14)

A composition comprising the host cell of claim 14 and a sterile cell culture medium.

### Claim 16 (depends on 15)

A composition comprising the host cell of claim 15 and a cryopreservative.

### Claim 17 (depends on 11)

A method for delivering a transgene to a subject comprising
administering a rAAV of claim 11 to a subject, wherein the rAAV comprises at least one transgene, and wherein the rAAV infects cells of a target tissue of the subject.

### Claim 18 (depends on 11)

A method for generating a somatic transgenic animal model comprising administering a recombinant rAAV of claim 11 to a non-human animal, wherein the rAAV comprises at least one transgene, and wherein the rAAV infects cells of a target tissue of the non-human animal.

### Claim 19 (depends on 17)

The method of claim 17, wherein the at least one transgene is a protein coding gene.

### Claim 20 (depends on 17)

The method of claim 17, wherein the at least one transgene encodes a small interfering nucleic acid.

### Claim 21 (depends on 20)

The method of claim 20, wherein the small interfering nucleic acid is a miRNA.

### Claim 22 (depends on 20)

The method of claim 20, wherein the small interfering nucleic acid is a miRNA sponge or TuD RNA that inhibits the activity of at least one miRNA in the subject or animal.

### Claim 23 (depends on 22)

The method of claim 22, wherein the miRNA is expressed in a cell of the target tissue

### Claim 24 (depends on 17)

The method of claim of claim 17, wherein the target tissue is skeletal muscle, heart, liver, pancreas, brain or lung.

### Claim 25 (depends on 18)

The method of claim 18, wherein the transgene expresses a transcript that comprises at least one binding site for a miRNA, wherein the miRNA inhibits activity of the transgene, in a tissue other than the target tissue, by hybridizing to the binding site.

### Claim 26 (depends on 23)

A method for generating a somatic transgenic animal model comprising administering a rAAV of claim 23 to a non-human animal, wherein the rAAV comprises at least one transgene, wherein the transgene expresses a transcript that comprises at least one binding site for a miRNA, wherein the miRNA inhibits activity of the transgene, in a tissue other than a target tissue, by hybridizing to the binding site of the transcript.

### Claim 27 (depends on 26)

The method of claim 26, wherein the transgene comprises a tissue specific promoter or inducible promoter.

### Claim 28 (depends on 27)

The method of claim 27, wherein the tissue specific promoter is a liver-specific thyroxin binding globulin (TBG) promoter, an insulin promoter, a glucagon promoter, a somatostatin promoter, a pancreatic polypeptide (PPY) promoter, a synapsin-1 (Syn) promoter, a creatine kinase (MCK) promoter, a mammalian desmin (DES) promoter, a α-myosin heavy chain (a-MHC) promoter, or a cardiac Troponin T (cTnT) promoter.

### Claim 29 (depends on 17)

The method of claim 17, wherein the rAAV is administered intravenously, transdermally, intraocularly, intrathecally, orally, intramuscularly, subcutaneously, intranasally, or by inhalation.

### Claim 30 (depends on 17)

The method of claim 17, wherein the subject is selected from a mouse, a rat, a rabbit, a dog, a cat, a sheep, a pig, and a non-human primate.

### Claim 31 (depends on 17)

The method of claim 17, wherein the subject is a human.

### Claim 32 (depends on 18)

A somatic transgenic animal model produced by the method of claim 18.

### Claim 33

A kit for producing a rAAV, the kit comprising:
a container housing an isolated nucleic acid having a sequence of any one of SEQ ID NO: 1 to 47.

### Claim 34 (depends on 33)

The kit of claim 33 further comprising instructions for producing the rAAV.

### Claim 35 (depends on 34)

The kit of claim 34 further comprising at least one container housing a recombinant AAV vector, wherein the recombinant AAV vector comprises a transgene.

### Claim 36 (depends on 2, 3, 4, 5)

A kit comprising:
a container housing a recombinant AAV having an isolated AAV capsid protein of any one of claims 2 to 5.

### Claim 37 (depends on 36)

The kit of claim 36, wherein the container is a syringe.

### Claim 38

An isolated AAV capsid protein encoded by a nucleic acid selected from the group consisting of SEQ ID NO: 1 to 47.

### Claim 39 (depends on 38)

The isolated AAV capsid protein of claim 38, wherein the capsid protein is a VP1 capsid protein.

### Claim 40 (depends on 38)

The isolated AAV capsid protein of claim 38, wherein the capsid protein is a VP2 capsid protein.

### Claim 41 (depends on 38)

The isolated capsid protein of claim 38, wherein the capsid protein is a VP3 capsid protein.

### Claim 42 (depends on 38, 39, 40, 41)

A pseudotyped AAV comprising the capsid protein of any one of claims 38 to 41.
